28 March 2024
28 March 2024
The Celeste phototherapy device uses light to treat symptoms in Parkinson’s patients linked to the circadian system.
Seyltx bought the programme for $2m and 20% equity and plans to advance ifenprodil in Phase II trials this year.
Early analysis revealed a rapid antidepressant response in 55% of the BPL-003 treated subjects by the second day.
IAM1363 will be evaluated both as a single agent and along with trastuzumab in the trial subjects.
The Phase I segment of the trial is designed to assess IMM-6-415's safety, tolerability, pharmacokinetics, and pharmacodynamics.
According to the initial trial results, the immunotherapy was safe and well-tolerated.
Pegozafermin is currently in a Phase III trial, with another on the way soon.
As Pfizer further expands its portfolio in the treatment of UC, the competition in the market increases.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
